Recent positive activities have encouraged buying the stock at its current price. Although it is a thinly traded stock, it has been in accumulation for a while; they have applied their cancer vaccine onchophage approval in Russia and their adjuvant system QS-21 is used by the glaxosmithkline in their Phase III lung cancer drug.
There are other Phase I drugs in pipe line. However these two are the potential candidates for this company to gain revenue. Like other biotechs this is a speculative stock.
I would recommend to invest only what you can lose. With this near term potential in mind, and a price that is so attractive, I have added some shares to my portfolio.
Disclosure: I am a long term investor and own shares of this company.
AGEN 1-yr chart